Journal
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Volume 29, Issue 4, Pages 185-196Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/YIC.0000000000000023
Keywords
allosteric; escitalopram (S-citalopram); major depressive disorder; paroxetine; selective serotonin reuptake inhibitor; serotonin; serotonin transporter; sertraline
Categories
Funding
- AstraZeneca
- Bionevia
- Bristol-Myers Squibb
- GlaxoSmithKline
- Johnson Johnson
- Lilly
- H. Lundbeck A/S
- Merck Co. Inc.
- M's Science
- Merz Pharmaceuticals
- Neurim Pharmaceuticals
- Otsuka
- Pfizer Inc.
- Pierre Fabre
- Roche Pharmaceuticals
- Sanofi-Aventis
- Sepracor Inc.
- Servier Laboratories
- Synosis
- Takeda
- Theracos
- Transcept
- UBC
- Xytis
- Wyeth
Ask authors/readers for more resources
It is known that newer antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs), provide advantages in tolerability over antidepressants such as the tricyclics. However, even within the SSRI class, differences in efficacy or tolerability exist between the individual drugs. Among the three most widely prescribed SSRIs are paroxetine, sertraline, and escitalopram. Escitalopram is commonly referred to as an SSRI, but also has well-documented allosteric properties, and thus can be further classed as an allosteric serotonin reuptake inhibitor. All three antidepressants are efficacious compared with placebo, but there is evidence that escitalopram is more effective than a range of other antidepressants. There are no direct data to regard either paroxetine or sertraline as a superior antidepressant. Escitalopram is superior compared with paroxetine, which has a less favorable tolerability profile. Paroxetine is associated with cholinergic muscarinic antagonism and potent inhibition of CYP2D6, and sertraline has moderate drug interaction issues in comparison with escitalopram. Overall, as an allosteric serotonin reuptake inhibitor that is somewhat different from classical SSRIs, escitalopram is the first choice judged by combined efficacy and tolerability, and nonclinical data have offered possible mechanisms through which escitalopram could be more efficacious, based on its interaction with orthosteric and allosteric binding sites at the serotonin transporter. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available